rilvegostomig + bevacizumab + tremelimumab

A pharmaceutical combination consisting of **rilvegostomig** (a bispecific monoclonal antibody targeting programmed cell death protein 1 [PD-1] and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains [TIGIT]), **bevacizumab** (a monoclonal antibody inhibiting vascular endothelial growth factor A [VEGF-A]), and **tremelimumab** (a monoclonal antibody inhibiting cytotoxic T-lymphocyte-associated protein 4 [CTLA-4]). This combination regimen is investigated as a first-line therapy for advanced hepatocellular carcinoma and other solid tumors, leveraging anti-angiogenic and multi-checkpoint immune-modulation mechanisms to augment antitumor immunity and clinical responses[1][5][7][8].